CompletedNot Applicable

Thrombo-Elastography Guided Management of ECMO

Canada61 participantsStarted 2020-06-03

Plain-language summary

Anticoagulation and coagulation management during ECMO is a challenge. Bleeding and clotting are major sources of morbidity and mortality. The currently used strategies are of poor evidence. This observational study wants to evaluate the use of automated thromboelastography (TEG 6s) to guide the management of coagulation and anticoagulation in patients supported by ECMO

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Consecutive patients admitted in Toronto General Hospital Medical Surgical ICU (MSICU) supported with ECMO. Patients cannulated before admission (ECMO retrieval) can also be included Exclusion Criteria: * Refusal of consent, unavailability or impossibility to process blood samples before ECMO cannulation

What they're measuring

Correlation between TEG (R-time K-TEG) and aPTT

Timeframe: 0-10 days

Correlation of TEG parameters with "classical" coagulation tests

Timeframe: 0-10 days

Ability of TEG data to identify patients at higher risk of bleeding (or clotting) during the course of ECMO

Timeframe: 0-10 days

Trial details

NCT IDNCT04268940

SponsorDamian Ratano

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-06-04

View on ClinicalTrials.gov More Extracorporeal Circulation of Blood; Thrombocytopenia trials